173 related articles for article (PubMed ID: 9472824)
21. Therapeutic radionuclides: production and decay property considerations.
Volkert WA; Goeckeler WF; Ehrhardt GJ; Ketring AR
J Nucl Med; 1991 Jan; 32(1):174-85. PubMed ID: 1988628
[TBL] [Abstract][Full Text] [Related]
22. The impact of tumor cell proliferation in radioimmunotherapy.
O'Donoghue JA
Cancer; 1994 Feb; 73(3 Suppl):974-80. PubMed ID: 8306287
[TBL] [Abstract][Full Text] [Related]
23. The radiobiology of conventional radiotherapy and its application to radionuclide therapy.
Dale R; Carabe-Fernandez A
Cancer Biother Radiopharm; 2005 Feb; 20(1):47-51. PubMed ID: 15778580
[TBL] [Abstract][Full Text] [Related]
24. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
[TBL] [Abstract][Full Text] [Related]
25. Experimental radioimmunotherapy.
Buchsbaum DJ; Langmuir VK; Wessels BW
Med Phys; 1993; 20(2 Pt 2):551-67. PubMed ID: 8492764
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
27. Calculated and simulated effects of heterogeneous dose distributions in radiotherapy using the dose volume inhomogeneity corrected biological equivalent dose formula with special reference to prostate cancer.
Lennernäs B; Albertsson P; Edgren M; Nilsson S
Oncol Rep; 2007 Nov; 18(5):1299-303. PubMed ID: 17914588
[TBL] [Abstract][Full Text] [Related]
28. Use of the fast Hartley transform for three-dimensional dose calculation in radionuclide therapy.
Erdi AK; Yorke ED; Loew MH; Erdi YE; Sarfaraz M; Wessels BW
Med Phys; 1998 Nov; 25(11):2226-33. PubMed ID: 9829250
[TBL] [Abstract][Full Text] [Related]
29. BEDVH-A method for evaluating biologically effective dose volume histograms: application to eye plaque brachytherapy implants.
Gagne NL; Leonard KL; Huber KE; Mignano JE; Duker JS; Laver NV; Rivard MJ
Med Phys; 2012 Feb; 39(2):976-83. PubMed ID: 22320806
[TBL] [Abstract][Full Text] [Related]
30. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
31. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab.
Wahl RL
Semin Oncol; 2003 Apr; 30(2 Suppl 4):31-8. PubMed ID: 12728405
[TBL] [Abstract][Full Text] [Related]
32. Radioimmunotherapy: recent results and future directions.
Wilder RB; DeNardo GL; DeNardo SJ
J Clin Oncol; 1996 Apr; 14(4):1383-400. PubMed ID: 8648397
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides.
Miller WH; Hartmann-Siantar C; Fisher D; Descalle MA; Daly T; Lehmann J; Lewis MR; Hoffman T; Smith J; Situ PD; Volkert WA
Cancer Biother Radiopharm; 2005 Aug; 20(4):436-49. PubMed ID: 16114992
[TBL] [Abstract][Full Text] [Related]
34. Radioimmunotherapy of solid cancers: A review.
Kairemo KJ
Acta Oncol; 1996; 35(3):343-55. PubMed ID: 8679266
[TBL] [Abstract][Full Text] [Related]
35. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
36. Internal dosimetry for systemic radiation therapy.
Fisher DR
Semin Radiat Oncol; 2000 Apr; 10(2):123-32. PubMed ID: 10727601
[TBL] [Abstract][Full Text] [Related]
37. Radioimmunotherapy with radioactive nanoparticles: biological doses and treatment efficiency for vascularized tumors with or without a central hypoxic area.
Bouchat V; Nuttens VE; Michiels C; Masereel B; Feron O; Gallez B; Vander Borght T; Lucas S
Med Phys; 2010 Apr; 37(4):1826-39. PubMed ID: 20443505
[TBL] [Abstract][Full Text] [Related]
38. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions.
Bouchet LG; Bolch WE; Goddu SM; Howell RW; Rao DV
J Nucl Med; 2000 Apr; 41(4):682-7. PubMed ID: 10768569
[TBL] [Abstract][Full Text] [Related]
39. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
40. Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model.
Roberson PL; Buchsbaum DJ
Cancer Res; 1995 Dec; 55(23 Suppl):5811s-5816s. PubMed ID: 7493351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
